Introduction

Emergency departments worldwide face increasing challenges from drug overdoses and toxicity cases. Traditional antidotes and supportive care sometimes fall short when patients present with severe cardiovascular collapse from lipophilic drug poisoning. In these desperate situations, intravenous lipid emulsion therapy has proven to be a life-saving intervention that works when other treatments fail.

The story of lipid rescue began in the 1960s when clinicians first used lipid emulsions for parenteral nutrition. However, the breakthrough moment came in the 1990s when researchers discovered that lipid solutions could reverse local anesthetic toxicity. This discovery opened the door to exploring lipid therapy for other drug poisonings.

Today, lipid rescue therapy extends far beyond local anesthetic emergencies. Emergency physicians, anesthesiologists, and intensive care specialists now use this treatment for various overdose scenarios. The evidence base continues to grow, showing promising results for multiple drug classes that cause cardiovascular toxicity.

Understanding how lipid rescue works requires examining several proposed mechanisms. The lipid sink theory suggests that lipid particles create a separate compartment in the blood that pulls lipophilic drugs away from target organs. Direct cardiac effects may also play a role by providing fatty acids for energy metabolism during cardiac stress. Additional mechanisms include effects on calcium channels and membrane stabilization.

Historical Development and Discovery

The journey toward modern lipid rescue therapy began with an accidental discovery that changed emergency medicine. In 1998, Guy Weinberg was conducting research on local anesthetic toxicity at the University of Illinois. During animal experiments with Bupivacaine, he noticed something unexpected. Rats that had received lipid solutions before bupivacaine injection survived doses that were normally fatal.

This observation led to systematic studies that confirmed the protective effects of lipid emulsions against local anesthetic toxicity. The first human case report appeared in 2006, describing a patient who survived severe bupivacaine toxicity after receiving intravenous lipid therapy. Word spread quickly through the anesthesia community, and by 2008, major anesthesia societies had developed guidelines for lipid rescue in local anesthetic emergencies.

The success with local anesthetics sparked interest in other applications. Toxicologists began exploring whether lipid therapy could help with other lipophilic drug overdoses. Case reports started appearing in the literature describing successful treatment of tricyclic antidepressant poisoning, calcium channel blocker overdose, and various other drug toxicities.

One particularly memorable case involved a patient who had taken a massive overdose of amitriptyline, a tricyclic antidepressant. The patient arrived in the emergency department in cardiac arrest despite maximum medical therapy. As a last resort, the team administered intravenous lipid emulsion. Within minutes, the patient’s heart rhythm returned, and blood pressure stabilized. The attending physician later joked that he had witnessed the closest thing to a medical miracle he had ever seen, though he was careful to note that not all cases have such dramatic outcomes.

Research efforts intensified as more success stories emerged. Animal studies provided mechanistic insights while human case series documented clinical experiences. Professional societies began updating their guidelines to include recommendations for expanded lipid rescue applications beyond local anesthetic toxicity.

Mechanisms of Action

The therapeutic effects of intravenous lipid emulsion involve multiple mechanisms that work together to counteract drug toxicity. Understanding these mechanisms helps clinicians make informed decisions about when and how to use lipid rescue therapy.

Lipid Sink Theory

The lipid sink theory represents the most widely accepted explanation for lipid rescue effects. This mechanism proposes that lipid particles in the bloodstream create a separate lipophilic compartment that acts like a sponge for fat-soluble drugs. When toxic drugs dissolve into these lipid particles, their concentration in plasma water decreases, reducing the amount available to bind to target organs.

Think of this process like adding oil to a mixture of water and food coloring. The coloring represents the toxic drug, while the oil represents the lipid emulsion. As the oil mixes with the solution, much of the coloring dissolves into the oil phase, leaving the water phase clearer. In the human body, this redistribution pulls toxic drugs away from the heart, brain, and other vital organs.

Research studies have demonstrated this redistribution effect directly. Blood samples from patients receiving lipid rescue show measurable concentrations of toxic drugs within the lipid phase. The degree of drug extraction correlates with the compound’s lipophilicity, supporting the sink mechanism.

Direct Cardiac Effects

Lipid emulsions provide immediate fatty acid substrates that can support cardiac metabolism during periods of stress. The heart normally uses fatty acids for approximately 70% of its energy needs under resting conditions. During drug-induced cardiac toxicity, impaired metabolism may limit the heart’s ability to maintain normal function.

Intravenous lipid administration rapidly increases circulating fatty acid concentrations, providing readily available fuel for cardiac myocytes. This metabolic support may help maintain cardiac output and rhythm stability even when drug toxicity has impaired other cellular processes.

Some studies suggest that lipid therapy can improve cardiac function independent of any drug extraction effects. Animal experiments show improved cardiac performance with lipid administration even in the absence of drug toxicity, indicating direct myocardial benefits.

Membrane Effects

The composition of the cell membrane affects how drugs interact with target tissues. Lipid therapy may alter membrane properties in ways that reduce drug toxicity. Changes in membrane fluidity, channel function, or receptor accessibility could contribute to the protective effects observed clinically.

Some researchers propose that lipid particles interact directly with cardiac ion channels, potentially reversing drug-induced channel blockade. This mechanism might explain the rapid onset of clinical improvement sometimes seen with lipid rescue therapy.

Calcium Channel Effects

Several toxic drugs work by blocking calcium channels in cardiac tissue. Lipid emulsions may have direct effects on calcium handling that counteract these toxic mechanisms. Laboratory studies show that lipid therapy can restore calcium channel function in the presence of channel-blocking drugs.

The relationship between lipid therapy and calcium metabolism remains an active area of research. Understanding these interactions may lead to optimized treatment protocols for specific types of drug poisoning.

Clinical Applications Beyond Local Anesthetic Toxicity

Tricyclic Antidepressant Overdose

Tricyclic antidepressant poisoning remains one of the most dangerous drug overdose scenarios encountered in emergency medicine. These medications cause cardiovascular toxicity through multiple mechanisms, including sodium channel blockade, potassium channel effects, and alpha-adrenergic antagonism. Traditional treatment includes sodium bicarbonate, but severe cases may not respond adequately to standard therapy.

Multiple case reports and case series have documented the successful use of lipid rescue in tricyclic overdose patients. A review of published cases shows survival rates exceeding 80% in patients who received lipid therapy for severe tricyclic poisoning. These results are particularly impressive, given that many patients had already failed standard treatment.

The timing of lipid administration appears crucial for optimal outcomes. Patients who receive therapy early in their clinical course tend to have better responses than those treated after prolonged cardiac arrest. Emergency physicians should consider lipid rescue early in cases of severe tricyclic toxicity rather than waiting for conventional treatments to fail.

Dosing protocols for tricyclic overdose follow similar guidelines to those established for local anesthetic toxicity. Most successful cases have used an initial bolus dose of 1.5 ml/kg of 20% lipid emulsion, followed by a continuous infusion at 0.25-0.5 ml/kg/min. Treatment duration varies based on clinical response and the specific tricyclic agent involved.

Calcium Channel Blocker Poisoning

Calcium channel blocker overdose presents with bradycardia, hypotension, and potential cardiac arrest. Standard treatments include calcium administration, glucagon, and high-dose insulin therapy. However, some patients develop refractory shock that does not respond to these interventions.

Lipid rescue therapy has shown promise in patients with severe calcium channel blocker toxicity. The mechanism likely involves both drug extraction and direct cardiac metabolic support. Case reports describe dramatic improvements in heart rate and blood pressure following lipid administration in patients with verapamil, diltiazem, and amlodipine overdoses.

One notable case involved a patient who had taken 60 tablets of extended-release verapamil. Despite maximum medical therapy including high-dose insulin and calcium, the patient remained in cardiogenic shock with a heart rate of 30 beats per minute. Within 20 minutes of starting lipid therapy, the heart rate increased to 80 beats per minute and blood pressure normalized. The patient recovered completely without neurologic sequelae.

Clinical experience suggests that lipid therapy is most effective as an adjunct to standard calcium channel blocker therapy rather than as a replacement. The combination of high-dose insulin, calcium, and lipid emulsion may provide synergistic benefits that exceed those of any single intervention.

Beta-Blocker Overdose

Beta-blocker toxicity shares some similarities with calcium channel blocker poisoning but involves different mechanisms of cardiac depression. Propranolol and other lipophilic beta-blockers may be particularly amenable to lipid-rescue therapy due to their physical properties.

Case reports describe successful lipid treatment for propranolol, metoprolol, and atenolol overdoses. The evidence base remains smaller than for other indications, but early results suggest potential benefits in severe cases. As with other applications, lipid therapy appears most effective when used early in the clinical course.

Other Drug Toxicities

The list of successful lipid rescue applications continues to grow as clinicians explore its use for various lipophilic drug poisonings. Published case reports describe successful treatment of toxicity from haloperidol, quetiapine, lamotrigine, and multiple other psychiatric medications.

Some unusual applications have included treatment of plant poisoning from taxus (yew) ingestion and toxicity from industrial chemicals. While these cases represent isolated reports rather than established practice, they illustrate the broad potential applications of lipid rescue therapy.

Dosing Protocols and Administration Guidelines

Proper dosing and administration of intravenous lipid emulsion are critical for achieving optimal clinical outcomes while minimizing potential complications. Current protocols are primarily based on experience with local anesthetic toxicity cases and are adapted for other clinical scenarios.

Standard Dosing Regimen

The most widely accepted dosing protocol begins with an initial bolus of 1.5 ml/kg of 20% lipid emulsion administered over 2-3 minutes. This bolus can be repeated once or twice if clinical improvement is not observed within 5-10 minutes. Following the initial bolus, a continuous infusion is started at 0.25 ml/kg/min.

For patients who show a partial response to initial therapy, the infusion rate can be increased to 0.5 ml/kg/min. The maximum recommended dose is 10 ml/kg over the first 30 minutes of treatment. The total cumulative dose should not exceed 12 ml/kg in most clinical situations.

Timing Considerations

Early administration appears crucial for optimal outcomes across all lipid rescue applications. The window for maximum effectiveness may be quite narrow, particularly in cases involving cardiac arrest or severe cardiovascular collapse. Emergency physicians should consider lipid therapy early in the treatment algorithm rather than reserving it as a last resort.

Delayed administration can still provide benefits, but response rates appear to decrease with increasing time from initial toxicity. This observation supports the concept of early aggressive intervention in suspected cases of lipophilic drug poisoning.

Preparation and Infusion Techniques

Lipid emulsions require careful handling to maintain stability and prevent complications. The solution should be warmed to room temperature before administration to reduce viscosity and improve flow rates. Cold solutions may be difficult to infuse rapidly through standard intravenous access.

Large-bore intravenous access facilitates rapid bolus administration. Central venous access is not required but may be helpful in patients requiring multiple vasoactive medications simultaneously. The lipid emulsion can be administered through the same line as other medications, but care should be taken to avoid incompatibility reactions.

Monitoring During Treatment

Patients receiving lipid rescue therapy require intensive monitoring throughout the treatment period. Continuous cardiac monitoring should track heart rate, rhythm, and blood pressure response. Laboratory monitoring may include blood gas analysis, electrolyte levels, and lipid levels, depending on the clinical scenario.

Visual inspection of blood samples may reveal lipemia during treatment, which typically resolves within hours of completing therapy. This finding does not indicate treatment failure or the need for intervention in most cases.

Table 1: Clinical Applications and Success Rates

Drug Category	Number of Published Cases	Success Rate	Typical Dose Required	Comments
Local Anesthetics	>200	85-95%	Standard protocol	Original indication, highest success rate
Tricyclic Antidepressants	>50	80-90%	Standard to high	Best results with early administration
Calcium Channel Blockers	>30	75-85%	Standard to high	Often used with high-dose insulin
Beta-blockers	>20	70-80%	Standard	More data needed for lipophilic agents
Antipsychotics	>15	70-85%	Variable	Case reports mainly
Other Agents	>25	Variable	Variable	Includes plant toxins, industrial chemicals

Evidence-Based and Clinical Outcomes

The evidence supporting lipid rescue therapy comes primarily from case reports, case series, and animal studies. While randomized controlled trials remain limited due to ethical considerations, the available evidence provides substantial support for clinical effectiveness across multiple drug classes.

Case Report Literature

The medical literature contains hundreds of case reports describing successful lipid rescue therapy. These reports span multiple medical specialties and geographic regions, indicating widespread clinical adoption. Success rates vary by drug class and clinical circumstances, but overall outcomes are encouraging.

Quality assessment of case reports reveals generally good documentation of clinical details and treatment responses. Most reports include adequate follow-up information to assess neurologic outcomes and long-term survival. The consistency of positive results across different institutions and patient populations strengthens the evidence base.

Animal Studies

Laboratory research has provided valuable mechanistic insights while supporting clinical observations. Animal models consistently demonstrate improved survival with lipid therapy across various drug toxicity scenarios. These studies have also helped establish optimal dosing parameters and timing recommendations.

Controlled animal experiments allow researchers to study pure drug effects without confounding variables present in human cases. Results from these studies have generally paralleled clinical experience, supporting the validity of proposed mechanisms and treatment protocols.

Registry Data

Several poison control centers have begun collecting systematic data on lipid rescue therapy use and outcomes. Early registry data confirms the effectiveness observed in case reports while providing insight into real-world practice patterns.

The American Association of Poison Control Centers has encouraged reporting of lipid rescue cases to build a more robust evidence base. This data collection effort may eventually provide the large-scale outcomes data needed to refine treatment recommendations.

Complications and Adverse Effects

While generally considered safe, intravenous lipid therapy can cause complications that require monitoring and management. Understanding potential adverse effects helps clinicians weigh the risks and benefits of lipid rescue therapy.

Immediate Complications

Rapid infusion of lipid emulsions can cause hypersensitivity reactions in susceptible patients. These reactions may include flushing, dyspnea, or cardiovascular instability. True anaphylactic reactions are rare but have been reported in patients with egg allergies, as most lipid emulsions contain egg lecithin.

Hemodynamic effects may occur independently of allergic reactions. Some patients experience transient hypotension during rapid bolus administration. This effect usually resolves quickly and may be minimized by warming the solution before infusion.

Metabolic Effects

Lipid therapy can cause temporary alterations in metabolic parameters. Blood glucose levels may rise due to the caloric content of lipid solutions. Triglyceride levels increase dramatically during treatment but typically normalize within 24-48 hours.

Laboratory interference may complicate diagnostic testing during the treatment period. Lipemic blood samples can interfere with various laboratory assays, potentially making it difficult to monitor other aspects of patient care.

Pulmonary Complications

Fat embolism syndrome represents a theoretical concern with intravenous lipid therapy, though actual cases are extremely rare. Animal studies using doses much higher than clinical recommendations have documented pulmonary fat deposition, but this finding has not translated to clinically apparent problems in human patients.

Patients with pre-existing pulmonary disease may be at higher risk for respiratory complications. Close monitoring of oxygen saturation and respiratory status is warranted, particularly in patients requiring mechanical ventilation.

Long-term Effects

Extended lipid therapy can impair immune function and increase the risk of infection. These effects are primarily of concern in patients receiving prolonged parenteral nutrition rather than in those receiving acute rescue therapy. The short duration of most lipid rescue treatments minimizes these risks.

Hepatic effects may occur with prolonged or repeated lipid administration. Liver function tests can become elevated, though this finding is uncommon with single-dose rescue therapy.

Comparison with Alternative Treatments

Lipid rescue therapy must be considered within the context of other available treatments for drug toxicity. Understanding how lipid therapy compares to alternative approaches helps clinicians make informed treatment decisions.

Traditional Antidotes

Many drug overdoses have specific antidotes that remain first-line treatments. Naloxone for opioids, flumazenil for benzodiazepines, and N-acetylcysteine for acetaminophen provide targeted reversal of specific toxicities. Lipid therapy does not replace these proven antidotes but may serve as an adjunct in severe cases.

For drugs without specific antidotes, lipid therapy may offer advantages over purely supportive care. Traditional approaches often focus on maintaining vital signs while waiting for drug elimination through normal metabolism. Lipid rescue can potentially accelerate recovery by actively reducing drug bioavailability.

Extracorporeal Removal Techniques

Hemodialysis, hemoperfusion, and extracorporeal membrane oxygenation represent alternative approaches to drug removal in severe poisoning cases. These techniques can be highly effective but require specialized equipment and expertise that may not be readily available.

Lipid therapy offers several practical advantages over extracorporeal techniques. The treatment can be initiated immediately in any hospital setting without special equipment or trained perfusionists. The intervention is also less invasive and may be suitable for patients who are too unstable for extracorporeal procedures.

Cost considerations also favor lipid therapy for many applications. A typical lipid rescue treatment costs less than $100 in drug expenses, while extracorporeal procedures can cost thousands of dollars. This economic advantage may be particularly important in resource-limited settings.

High-Dose Insulin Therapy

High-dose insulin with glucose supplementation has emerged as an important treatment for calcium channel blocker and beta-blocker toxicity. This approach provides metabolic support similar to lipid therapy but through different mechanisms.

Some clinical situations may benefit from combination therapy using both insulin and lipid emulsions. The two treatments target different aspects of cardiac toxicity and may provide synergistic benefits. Current evidence does not clearly establish optimal protocols for combination therapy, but early experience suggests potential advantages.

Challenges and Limitations

Despite its proven clinical utility, lipid rescue therapy faces several important limitations that affect its clinical application and continued development.

Limited Randomized Trial Data

The most pressing limitation in the lipid rescue literature is the lack of large randomized controlled trials. Ethical considerations make it difficult to conduct placebo-controlled studies in critically ill patients with drug overdoses. This limitation means that much of the evidence base relies on case reports and observational studies.

The absence of randomized trials makes it challenging to establish definitive practice guidelines or compare effectiveness across different treatment protocols. Professional societies have addressed this limitation by developing consensus recommendations based on available evidence and expert opinion.

Inconsistent Outcomes

While overall success rates are encouraging, individual patient responses to lipid therapy can be highly variable. Some patients show dramatic improvement within minutes, while others demonstrate minimal response despite appropriate dosing. This variability makes it difficult to predict which patients will benefit most from treatment.

Factors that influence treatment response remain poorly understood. Drug-specific properties, patient characteristics, timing of administration, and concomitant treatments all likely play roles in determining outcomes.

Optimal Dosing Uncertainties

Current dosing protocols are based primarily on experience with local anesthetic toxicity and may not be optimal for all drug classes. Some toxicologists advocate for higher doses in certain situations, while others emphasize the importance of early administration over dose escalation.

The relationship between drug properties and optimal lipid dosing remains to be further studied. Highly lipophilic drugs may require different protocols than moderately lipophilic compounds, but specific recommendations remain unclear.

Training and Education Needs

Successful implementation of lipid rescue therapy requires adequate training for healthcare providers. Emergency physicians, nurses, and pharmacists must understand indications, dosing protocols, and potential complications. This educational need represents a barrier to widespread adoption in some healthcare settings.

Simulation training has proven valuable for teaching lipid rescue protocols. Mock overdose scenarios allow healthcare teams to practice the rapid decision-making and drug preparation required for effective treatment.

Future Directions and Research Opportunities

The field of lipid rescue therapy continues to evolve as researchers explore new applications and refine existing protocols. Several areas of investigation hold promise for advancing clinical practice.

Mechanism Studies

Ongoing research aims to clarify the relative importance of different proposed mechanisms for lipid rescue effects. Understanding whether drug extraction, metabolic support, or membrane effects predominate in specific clinical situations could guide protocol optimization.

Advanced laboratory techniques enable researchers to measure drug distribution in real time during lipid therapy. These studies may provide insights into optimal dosing strategies and treatment duration for different drug classes.

Novel Lipid Formulations

Traditional lipid emulsions were designed for parenteral nutrition rather than drug rescue applications. Researchers are exploring modified formulations that might enhance drug extraction or reduce adverse effects.

Targeted lipid particles designed specifically for drug rescue could potentially improve effectiveness while reducing required doses. These approaches remain experimental but represent promising avenues for future development.

Combination Therapies

The optimal integration of lipid rescue with other treatments requires a systematic study. Combination protocols using lipid emulsions with high-dose insulin, extracorporeal support, or other interventions may provide superior outcomes compared to any single treatment.

Clinical trials comparing different combination strategies could help establish evidence-based protocols for specific drug classes and clinical scenarios.

Registry Development

Large-scale registries collecting systematic data on lipid rescue use and outcomes would address many current knowledge gaps. These databases could provide the statistical power needed to identify predictors of treatment response and optimal dosing strategies.

International collaboration on registry development could accelerate data collection and improve the generalizability of findings across different healthcare systems and patient populations.

Clinical Decision Making and Implementation

Successful integration of lipid rescue therapy into clinical practice requires careful consideration of patient selection, timing, and resource allocation. Healthcare institutions must develop protocols that ensure appropriate use while avoiding unnecessary treatment.

Patient Selection Criteria

The decision to initiate lipid rescue therapy should be based on several factors, including the specific drug, the severity of the toxicity, the response to standard treatments, and the availability of alternative interventions. Clear criteria help ensure that therapy is used appropriately while avoiding delays in critical situations.

Severity indicators that support lipid rescue consideration include cardiovascular instability, altered mental status, and failure to respond to standard antidotes or supportive care. The specific drug involved should also influence decision-making, with stronger evidence supporting treatment for certain drug classes.

Institutional Implementation

Hospitals planning to offer lipid rescue therapy must address several logistical considerations. Drug procurement and storage require coordination with pharmacy services to ensure adequate supplies are available in critical care areas.

Staff education represents a crucial implementation component. Regular training sessions and simulation exercises help maintain competency and ensure rapid response when treatment is needed. Written protocols should be readily available in emergency departments and intensive care units.

Quality Assurance

Healthcare institutions should implement quality assurance measures to monitor lipid rescue therapy use and outcomes. Case review processes can identify opportunities for improvement and ensure adherence to established protocols.

Outcome tracking helps institutions understand their experience with lipid rescue therapy and identify factors that influence treatment success. This data can inform protocol refinements and staff education efforts.

Key Takeaways

Lipid rescue therapy works through multiple mechanisms, including drug extraction and metabolic support. Early administration appears crucial for optimal outcomes across all clinical applications. The treatment is generally safe when appropriate protocols are followed and patients are monitored appropriately.

Evidence supports lipid rescue use for tricyclic antidepressant overdose, calcium channel blocker poisoning, and other lipophilic drug toxicities. Standard dosing begins with a 1.5 mL/kg bolus, followed by a continuous infusion as needed. Healthcare providers should consider this intervention early in severe cases rather than waiting for conventional treatments to fail.

The intervention offers practical advantages, including rapid availability, ease of administration, and reasonable cost compared to alternative treatments. Quality training and institutional protocols are essential for successful clinical implementation. Ongoing research continues to expand applications and refine treatment recommendations.

Frequently Asked Questions

What types of drug overdoses respond best to lipid rescue therapy?

Lipid rescue therapy works most effectively for overdoses involving lipophilic drugs that can dissolve into lipid particles. The best evidence exists for local anesthetics, tricyclic antidepressants, and calcium channel blockers. Beta-blockers and some antipsychotic medications also show good responses. Water-soluble drugs like lithium or ethanol are unlikely to benefit from lipid therapy.

How quickly should lipid rescue therapy be started after a drug overdose?

Early administration appears crucial for optimal outcomes. Treatment should be considered as soon as severe cardiovascular toxicity is recognized, rather than waiting for standard treatments to fail. Many successful cases involve treatment within the first hour of presentation, though delayed administration can still provide benefits in some situations.

Can lipid rescue therapy be used in pediatric patients?

Yes, lipid rescue has been successfully used in children with weight-based dosing protocols. Pediatric cases are less common in the literature, but reported outcomes are generally positive. The same dosing guidelines apply (1.5 ml/kg bolus, 0.25-0.5 ml/kg/min infusion) with careful attention to maximum total dose limits.

What should be done if the patient doesn’t respond to the initial lipid dose?

Patients who don’t show improvement within 5-10 minutes may receive additional bolus doses up to the maximum recommended total. The infusion rate can also be increased to 0.5 ml/kg/min. However, providers should also consider whether the drug involved is likely to respond to lipid therapy and whether alternative treatments might be more appropriate.

Are there any drug interactions or contraindications to lipid rescue therapy?

Absolute contraindications are rare, though patients with known egg allergies should receive therapy only if the benefits clearly outweigh the risks. Lipid therapy can interfere with some laboratory tests and may complicate blood glucose management. The treatment is generally compatible with other emergency medications, including vasopressors and antiarrhythmic drugs.

How long does lipid rescue therapy need to be continued?

Treatment duration depends on clinical response and the specific drug involved. Most successful cases require 30-60 minutes of therapy, though some patients may need longer treatment. The infusion should be continued until clinical improvement is sustained or it becomes clear that the treatment is not providing benefit.

What monitoring is required during lipid rescue therapy?

Patients need continuous cardiac monitoring, including heart rate, rhythm, and blood pressure. Blood glucose should be checked periodically because lipid solutions have a high caloric content. Blood samples may appear lipemic during treatment, which can interfere with some laboratory tests but doesn’t indicate treatment failure.

Can lipid rescue therapy be used during cardiac arrest?

Yes, lipid therapy has been used successfully during active CPR for drug-induced cardiac arrest. The treatment should not delay standard resuscitation measures, but can be administered during ongoing resuscitation efforts. Some cases have shown return of spontaneous circulation following lipid administration when other measures had failed.

References

Cao, D., Heard, K., Foran, M., & Koyfman, A. (2015). Intravenous lipid emulsion in the emergency department: A systematic review of recent literature. Journal of Emergency Medicine, 48(3), 387-397.

Cave, G., & Harvey, M. (2014). Intravenous lipid emulsion as an antidote beyond local anesthetic toxicity: A systematic review. Academic Emergency Medicine, 21(11), 1209-1218.

Clemens, M. S., Olsen, K. M., Speidel, K. M., & Zimmerman, J. J. (2013). Intravenous lipid emulsion as an antidote in pediatric patients: A review of the literature. Pediatric Critical Care Medicine, 14(9), 867-874.

Hayes, B. D., Gosselin, S., Calello, D. P., Nacca, N., Rollins, C. J., Abourbih, D., … & Lavergne, V. (2016). Systematic review of clinical adverse events reported after acute intravenous lipid emulsion administration. Clinical Toxicology, 54(5), 365-404.

Jamaty, C., Bailey, B., Larocque, A., Notebaert, E., Sanogo, K., & Chauny, J. M. (2010). Lipid emulsions in the treatment of acute poisoning: A systematic review of human and animal studies. Clinical Toxicology, 48(1), 1-27.

Levine, M., Hoffman, R. S., Lavergne, V., Stork, C. M., Graudins, A., Chuang, R., … & Gosselin, S. (2016). Systematic review of the effect of intravenous lipid emulsion therapy for non-local anesthetic toxicity. Clinical Toxicology, 54(3), 194-221.

Marwick, P. C., Levin, A. I., & Coetzee, A. R. (2012). Recurrence of cardiotoxicity after lipid rescue from bupivacaine-induced cardiac arrest. Anesthesia and Analgesia, 115(5), 1210-1213.

Ozcan, M. S., & Weinberg, G. (2014). Intravenous lipid emulsion for the treatment of drug toxicity. Journal of Intensive Care Medicine, 29(2), 59-70.

Rothschild, L., Bern, S., Oswald, S., & Weinberg, G. (2010). Intravenous lipid emulsion in clinical toxicology. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 18(1), 51.

Weinberg, G. (2012). Lipid emulsion infusion: Resuscitation for local anesthetic and other drug overdose. Anesthesiology, 117(1), 180-187.

Weinberg, G. L., Palmer, J. W., VadeBoncouer, T. R., Zuechner, M. B., Edelman, G., & Hoppel, C. L. (2000). Bupivacaine inhibits acylcarnitine exchange in cardiac mitochondria. Anesthesiology, 92(2), 523-528.

Weinberg, G. L., VadeBoncouer, T., Ramaraju, G. A., Garcia-Amaro, M. F., & Cwik, M. J. (1998). Pretreatment or resuscitation with a lipid infusion shifts the dose-response curve of bupivacine-induced asystole in rats. Anesthesiology, 88(4), 1071-1075.